Floatz logo

Enasidenib

Myelodysplastic Syndrome With Excess Blasts-2

Stichting Hemato-Oncologie voor Volwassenen NederlandSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Myelodysplastic Syndrome With Excess Blasts-2 cohort.

Asset / SponsorPhaseRating
Fludarabine
Sumithira Vasu
Phase 2BB
Gilteritinib
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3BB
Cytosin-Arabinosid
Sumithira Vasu
Phase 2BB
Midostaurin
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3B
METHOTREXATE
Fred Hutchinson Cancer Center
Phase 2B

View all 29 →

Same molecule, other indications

Enasidenib is also rated in:

IDH2 Gene MutationDormant
BB
Indicative ·
64 / 100
View asset →
Isocitrate DehydrogenaseDormant
BB
Indicative ·
64 / 100
View asset →
myeloid leukemiaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →